精品文档---下载后可任意编辑GOLD2024 年 GOLD2024 在病情评估和药物推举异同及医生依从性分析的开题报告摘要：本文旨在比较 2024 年和 2024 年 GOLD 指南在 COPD 病情评估和药物推举方面的异同，并分析医生对指南的依从性。采纳文献综述法和患者案例分析法，对 2024 年和 2024 年 GOLD 指南进行比较分析，并对两个时期的患者进行病情评估和药物推举。结果发现，2024 年 GOLD指南对 COPD 的分期和药物推举细节更加完善，建议加强肺功能检查和症状评估，强调早期干预和个体化治疗；而 2024 年 GOLD 指南对COPD 的药物推举更为简略，着重强调支气管舒张剂的使用。此外，医生对指南的依从性较低，需要加强宣传和培训。关键词：COPD；GOLD 指南；病情评估；药物推举；医生依从性Abstract:The purpose of this paper is to compare the differences and similarities between the 2024 and 2024 GOLD guidelines in COPD assessment and drug recommendations, and to analyze the compliance of doctors with the guidelines. Literature review and patient case analysis were used to compare and analyze the 2024 and 2024 GOLD guidelines, and to assess and recommend drugs for patients in the two periods. The results showed that the 2024 GOLD guidelines were more detailed in the staging and drug recommendations of COPD, suggesting that lung function tests and symptom assessments should be strengthened, and emphasizing early intervention and personalized treatment; while the 2024 GOLD guidelines were more concise in the drug recommendations for COPD, focusing on the use of bronchodilators. In addition, the doctors’ compliance with the guidelines was low, and more promotion and training were needed.Keywords: COPD; GOLD guidelines; assessment; drug recommendation; doctor compliance
